Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: Antitumor efficacy and immunoregulation in a nonimmunogenic tumor model

Molecular Therapy

Volumn 5, Issue 4, 2002, Pages 405-412

  Pützer, Brigitte M ^a   Rödicker, Florian ^a   Hitt, Mary M ^b   Stiewe, Thorsten ^a   Esche, Helmut ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenoviral vector; Antigen presentation machinery; B7.1; Gene therapy; Interleukin 12; Pancreatic cancer

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; INTERLEUKIN 12; PROTEASOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS DUCT; REGULATORY MECHANISM; TUMOR IMMUNITY; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0036230069     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0570     Document Type: Article

References (50)

1. How tumors escape immune destruction and what we can do about it
2. Human tumor antigens recognized by T lymphocytes
3. Gene vectors for cytokine expression in vivo
4. Antitumor activities of IL-12 and mechanisms of action
5. Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma
6. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells
7. Interleukin-12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
8. Large nontransplanted hepatocellular carcinoma in wood-chucks: Treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes
9. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
10. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors
11. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells
12. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing
13. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
14. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology
15. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
16. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor transfer
17. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor
18. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene
19. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma
20. Phase I trial of interferon-γ retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma
21. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study
22. Murine models of cancer cytokine gene therapy using interleukin-12
23. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice
24. Upregulation of antitumor immunity by IL-12 gene-transfected AK-5 tumor cells in vivo
25. Application of interleukin 12 to antitumor cytokine and gene therapy
26. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity
27. Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone
28. Tumor-rejection antigens recognized by T lymphocytes
29. Tumor antigens recognized by T lymphocytes
30. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level
31. B7-1 and interleukin 12 synergistically induce effective antitumor immunity
32. Immune regulation: A critical link between NK cells and CTLs
33. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma
34. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1)
35. TAP off-tumors on
36. A reassessment of the role of B7-1 expression in tumor rejection
37. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency
38. TAP expression provides a general method for improving the recognition of malignant cells in vivo
39. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumor response and may generate systemic protective immunity
40. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors
41. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model
42. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
43. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization
44. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4
45. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL
46. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2
47. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation
48. Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy
49. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines
50. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice